Format

Send to

Choose Destination
Stat Biosci. 2016 Jun;8(1):99-128. Epub 2014 Dec 4.

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

Author information

1
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.
2
Department of Thoracic, Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.
3
Department of Internal Medicine, Yale School of Medicine, 333 Cedar Street, WWW221, New Haven, CT 06520, USA.

Abstract

We propose a Bayesian two-stage biomarker-based adaptive randomization (AR) design for the development of targeted agents. The design has three main goals: (1) to test the treatment efficacy, (2) to identify prognostic and predictive markers for the targeted agents, and (3) to provide better treatment for patients enrolled in the trial. To treat patients better, both stages are guided by the Bayesian AR based on the individual patient's biomarker profiles. The AR in the first stage is based on a known marker. A Go/No-Go decision can be made in the first stage by testing the overall treatment effects. If a Go decision is made at the end of the first stage, a two-step Bayesian lasso strategy will be implemented to select additional prognostic or predictive biomarkers to refine the AR in the second stage. We use simulations to demonstrate the good operating characteristics of the design, including the control of per-comparison type I and type II errors, high probability in selecting important markers, and treating more patients with more effective treatments. Bayesian adaptive designs allow for continuous learning. The designs are particularly suitable for the development of multiple targeted agents in the quest of personalized medicine. By estimating treatment effects and identifying relevant biomarkers, the information acquired from the interim data can be used to guide the choice of treatment for each individual patient enrolled in the trial in real time to achieve a better outcome. The design is being implemented in the BATTLE-2 trial in lung cancer at the MD Anderson Cancer Center.

KEYWORDS:

Adaptive Design; Bayesian Lasso; Outcome-Adaptive Randomization; Personalized Medicine; Predictive and Prognostic Biomarkers; Targeted Therapy; Variable Selection

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center